Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valproic Acid and Simvastatin With Chemotherapy in Untreated Metastatic Pancreatic Cancer
NCT05821556Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Jun 2023
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of valproic acid and simvastatin in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by National Cancer Institute. Primary endpoint: Progression Free Survival at 40 months. Started Jun 2023; status: recruiting.
02
Drugs
valproic acidsimvastatin
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT05821556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05821556.